[go: up one dir, main page]

ES2148224T3 - Formulacion de rapamicina para inyecciones intravenosas. - Google Patents

Formulacion de rapamicina para inyecciones intravenosas.

Info

Publication number
ES2148224T3
ES2148224T3 ES93908637T ES93908637T ES2148224T3 ES 2148224 T3 ES2148224 T3 ES 2148224T3 ES 93908637 T ES93908637 T ES 93908637T ES 93908637 T ES93908637 T ES 93908637T ES 2148224 T3 ES2148224 T3 ES 2148224T3
Authority
ES
Spain
Prior art keywords
rapamycin
solution
weight percent
polyethylene glycol
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908637T
Other languages
English (en)
Inventor
Robert Paul Waranis
Maureen Murphy Harrison
Thomas Waymond Leonard
Robin Peter Enever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2148224T3 publication Critical patent/ES2148224T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA SOLUCION DE RAPAMICIN INYECTABLE, ACUOSA QUE SE OBTIENE MEDIANTE UN PROCESO QUE COMPRENDE LA MEZCLA DE ENTRE UN 0.1 Y UN 10% DEL PESO DE UNA SOLUCION CONCENTRADA DE RAPAMICIN EN N,NDIMETILACETAMIDO, A CONCENTRACIONES DEL RAPAMICIN QUE OSCILAN ENTRE 0.25 MG/ML Y 100 MG/ML, CON UNA SOLUCION DILUYENTE QUE COMPRENDE ENTRE UN 0.1 Y UN 10% DEL PESO DE AGUA DE UNO O MAS ESTERES DE SORBITAN DE POLIOXIETILENO, ENTRE UN 10 Y 60% DEL PESO DE GLICOL DE POLIETILENO 200 O 300 O AMBOS Y ENTRE UN 36 Y UN 90% DEL VOLUMEN DE AGUA, EN DONDE LA CONCENTRACION DEL RAPAMICIN EN LA SOLUCION COMBINADA OSCILA ENTRE 0.05 MG/ML Y 5.0 MG/ML.
ES93908637T 1992-03-30 1993-03-29 Formulacion de rapamicina para inyecciones intravenosas. Expired - Lifetime ES2148224T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86053092A 1992-03-30 1992-03-30

Publications (1)

Publication Number Publication Date
ES2148224T3 true ES2148224T3 (es) 2000-10-16

Family

ID=25333426

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908637T Expired - Lifetime ES2148224T3 (es) 1992-03-30 1993-03-29 Formulacion de rapamicina para inyecciones intravenosas.

Country Status (21)

Country Link
US (1) US5530006A (es)
EP (1) EP0633783B1 (es)
JP (1) JPH07505628A (es)
KR (1) KR950700750A (es)
AT (1) ATE193652T1 (es)
AU (1) AU681579B2 (es)
CA (1) CA2132636C (es)
DE (1) DE69328829T2 (es)
DK (1) DK0633783T3 (es)
ES (1) ES2148224T3 (es)
GR (1) GR3034293T3 (es)
HU (2) HUT70947A (es)
LV (1) LV12657B (es)
MX (1) MX9301740A (es)
NZ (1) NZ251628A (es)
PH (1) PH30923A (es)
PT (1) PT633783E (es)
SG (1) SG49652A1 (es)
TW (1) TW427903B (es)
WO (1) WO1993019763A1 (es)
ZA (1) ZA932224B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
CN1104724C (zh) * 1996-01-08 2003-04-02 株式会社东芝 信息记录方法以及重放方法
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
AU2001247401A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ATE411321T1 (de) 2000-09-19 2008-10-15 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
US20050220835A1 (en) * 2004-03-30 2005-10-06 Jayaraman Ramesh B Agent eluting bioimplantable devices and polymer systems for their preparation
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
EP1865770A4 (en) * 2005-04-07 2010-12-29 Nitromed Inc ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF NOS3
WO2007041681A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
EP1945030A4 (en) * 2005-10-04 2009-10-21 Nitromed Inc GENETIC RISK ASSESSMENT FOR HEART FAILURE: INFLUENCE OF GENETIC VARIATION ON GLY389ARG POLYMORPHISM OF THE BETA 1 ADRENERGENIC RECEPTOR
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
WO2007120555A2 (en) * 2006-04-10 2007-10-25 Nitromed, Inc, Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
EP1938800A1 (en) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
AU2007339773B2 (en) * 2006-12-27 2011-03-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
IN2012DN02764A (es) 2009-08-31 2015-09-18 Amplimmune Inc
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2011135580A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
WO2012092421A2 (en) 2010-12-30 2012-07-05 Surmodics, Inc. Composition for intravascular delivery of therapeutic composition
US9610250B2 (en) 2012-04-12 2017-04-04 Yale University Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
EP2997373A1 (en) 2013-05-17 2016-03-23 MedImmune, LLC Receptors for b7-h4
US10603325B2 (en) 2014-10-29 2020-03-31 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
US10864170B2 (en) 2015-09-04 2020-12-15 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
BR112019002127A2 (pt) 2016-08-03 2019-09-17 Nextcure Inc proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
EP3515478B1 (en) 2016-09-21 2024-02-28 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
US20210115378A1 (en) 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
EP3790592A1 (en) 2018-05-09 2021-03-17 Yale University Particles for spatiotemporal release of agents
CN119700703A (zh) 2019-01-17 2025-03-28 佐治亚技术研究公司 含有氧化的胆固醇的药物递送系统
WO2021258042A1 (en) 2020-06-19 2021-12-23 Yale University Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627886A (en) * 1968-04-15 1971-12-14 Hoffmann La Roche Methods of solubilizing coumermycin employing urea, dimethylacetamide or mixtures thereof
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4707470A (en) * 1985-05-17 1987-11-17 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
US5202241A (en) * 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제

Also Published As

Publication number Publication date
WO1993019763A1 (en) 1993-10-14
US5530006A (en) 1996-06-25
HU211841A9 (en) 1995-12-28
HUT70947A (en) 1995-11-28
AU681579B2 (en) 1997-09-04
DK0633783T3 (da) 2000-09-25
EP0633783A1 (en) 1995-01-18
PT633783E (pt) 2000-11-30
AU3939193A (en) 1993-11-08
EP0633783B1 (en) 2000-06-07
KR950700750A (ko) 1995-02-20
GR3034293T3 (en) 2000-12-29
ZA932224B (en) 1994-09-29
TW427903B (en) 2001-04-01
HU9402821D0 (en) 1994-12-28
SG49652A1 (en) 1998-06-15
ATE193652T1 (de) 2000-06-15
PH30923A (en) 1997-12-23
CA2132636A1 (en) 1993-10-14
DE69328829T2 (de) 2000-10-12
LV12657A (lv) 2001-05-20
LV12657B (lv) 2001-09-20
MX9301740A (es) 1993-09-01
NZ251628A (en) 1996-07-26
JPH07505628A (ja) 1995-06-22
DE69328829D1 (de) 2000-07-13
CA2132636C (en) 2002-12-17

Similar Documents

Publication Publication Date Title
ES2148224T3 (es) Formulacion de rapamicina para inyecciones intravenosas.
FI944536A0 (fi) Rapamysiiniformulaatio iv-injektiota varten
DK0650729T3 (da) Rapamycin-præparater til intravenøs injektion
DE69306810D1 (de) Stabilisierung von fluorkohlenstoff-emulsionen
FI944448A0 (fi) Stabiloitu farmaseuttinen koostumus ja stabiloiva liuotin
ES2173124T3 (es) Composicion de dermatano sulfato utilizado como antitrombotico.
ES2171444T3 (es) Una solucion intravenosa que disminuye las perdidas de proteinas y de agua corporales.
ES2151255T3 (es) Poliaminoacido para fomentar la absorcion de insecticida.
PE20000018A1 (es) Composiciones farmaceuticas a base de dalfopristina y de quinupristina y su preparacion
TR27766A (tr) Zirai kimyasal aktif bilesenler olarak kullanilabilen diokzolan türevleri.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633783

Country of ref document: ES